About
About Harbin Medisan Pharmaceutical Co., Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium folinate for injection, hydroxylcamptothecine injection, tropisetron hydrochloride for injection, tropisetron hydrochloride and glucose injection, gabexate mesylate for injection, bismuth potassium citrate granules, pantoprazole sodium for injection, ambroxol hydrochloride and glucose injection, asarone for injection, paracetamol and tramadol hydrochloride tablets, rifamycin sodium for injection, lornoxicam for injection, vecuronium bromide for injection, and vitamin c for injection. It also provides manufacture, sale, and retail of pharmaceutical, drug development, technology investment consulting, logistics and transportation, medical devices, food, and cosmetics. Harbin Medisan Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Harbin, China.
Research context
Harbin Medisan Pharmaceutical Co., Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Visit company website
5 years, 7 months ago
Harbin Medisan Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 94.5% above its 200 day moving average.
From a valuation standpoint, the stock is 61.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
Harbin Medisan Pharmaceutical Co., Ltd's total revenue sank by 28.0% to $339M since the same quarter in the previous year.
Its net income has dropped by 122.5% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 380.3% to $25M since the same quarter in the previous year.
Based on the above factors, Harbin Medisan Pharmaceutical Co., Ltd gets an overall score of 3/5.